Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
AKAkari Therapeutics, Plc logo

Akari Therapeutics, Plc (AKTX)

NASDAQ Capital Market · Currency in USD
$8.23 ▲ +0.13 (+1.54%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$8.10
Open
$8.00
Day's Range
$7.84 – $8.45
52 Week Range
$3.02 – $33.60
Volume
14,391
Avg. Volume
67,824
Market Cap
$18.88M
Beta (5Y Monthly)
1.44
PE Ratio (TTM)
--
EPS (TTM)
-$17.28
Earnings Date
Dec 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$24.75

Profile: Akari Therapeutics, Plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
Abizer Gaslightwala

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.

Earnings

Next report: Fri, Dec 4, 2026
EPS estimate -$2.24
DateEst.Actual
Aug 13, 2026-$1.04-$272.00Miss
May 19, 2026-$1.33-$9.74Miss
Mar 30, 2026-$1.80-$2.99Miss
Nov 13, 2025-$1.60-$4.00Miss
Aug 13, 2025-$3.60-$2.40Beat
May 15, 2025–-$5.40

Analyst view

Consensus price target
$24.75 ▲ +200.9%
Range $19.50 – $30.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on AKTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.